First Impressions from the DOJ/FTC Listening Session on Drug-Price Competition

Kristian Stout July 7, 2025

Truth on the Market View Original Source

• 
  Back
  to Top

Last week’s “listening session” on pharmaceutical competition, hosted jointly by the U.S. Justice Department (DOJ) and Federal Trade Commission (FTC), may go down as an important precursor to the Trump administration’s promised campaign to lower drug prices. While billed as a fact-finding exercise, the discussion revealed competing visions to reform the U.S. pharmaceutical ecosystem, with potentially far-reaching implications for innovation incentives and patient access.

Read the full piece here.